Product Information
BUTALBITAL-ASPIRIN-CAFFEINE 50-325-40 MG CAPSULE is a generic product labeled by Sandoz Inc., priced at $0.9482 per EA under NDC 00781227001. Its NADAC has been published 100 times since Nov 6, 2024.
FDA first approved this application on Oct 11, 1985. Its Orange Book therapeutic-equivalence code is AA.
Strength
325; 50; 40 mg/1; mg/1; mg/1
Manufacturer
Sandoz Inc.NDC
00781227001
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ASPIRIN; BUTALBITAL; CAFFEINEApproval Type
Generic (ANDA)
FDA Application
ANDA086996FDA Approved
10/11/1985
TE Code
AA
On Market Since
9/3/2024
Pharmacological Classes
Price Statistics
The NADAC for BUTALBITAL-ASPIRIN-CAFFEINE 50-325-40 MG CAPSULE has been published 100 times since Nov 6, 2024, and over the history we have for it it has risen 26.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.9482 per EA |
|---|---|
| All-time high | $1.0486 (Sep 10, 2025) |
| All-time low | $0.3623 (Nov 20, 2024) |
| 52-week high | $1.0362 |
| 52-week low | $0.9482 |
| Median price | $0.9783 |
| Average price | $0.9181 |
| Largest weekly change | +59.7% (Dec 18, 2024) |
| Weeks tracked | 100 |
| Tracking since | Nov 6, 2024 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Sandoz Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Butalbital, aspirin, and caffeine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Barbiturate class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of BUTALBITAL-ASPIRIN-CAFFEINE 50-325-40 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for BUTALBITAL-ASPIRIN-CAFFEINE 50-325-40 MG CAPSULE, manufactured by Sandoz Inc., is $0.9482 per EA (NDC 00781227001), effective Sep 30, 2026.
How has the price of BUTALBITAL-ASPIRIN-CAFFEINE 50-325-40 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for BUTALBITAL-ASPIRIN-CAFFEINE 50-325-40 MG CAPSULE has risen 26.5%. It has been tracked across 100 weekly CMS publications since Nov 6, 2024.
What are the highest and lowest recorded NADAC prices for BUTALBITAL-ASPIRIN-CAFFEINE 50-325-40 MG CAPSULE?
Since Nov 6, 2024, the NADAC for BUTALBITAL-ASPIRIN-CAFFEINE 50-325-40 MG CAPSULE has ranged from a low of $0.3623 (Nov 20, 2024) to a high of $1.0486 (Sep 10, 2025), with a median of $0.9783 per EA.
Are there cheaper alternatives to BUTALBITAL-ASPIRIN-CAFFEINE 50-325-40 MG CAPSULE?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as BUTALBITAL-ASPIRIN-CAFFEINE 50-325-40 MG CAPSULE in a comparable dosage form, but none are currently priced below it.
Who manufactures BUTALBITAL-ASPIRIN-CAFFEINE 50-325-40 MG CAPSULE?
BUTALBITAL-ASPIRIN-CAFFEINE 50-325-40 MG CAPSULE (NDC 00781227001) is labeled by Sandoz Inc., and CMS classifies it as a generic product.